BRPI0517341A - composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1 - Google Patents
composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1Info
- Publication number
- BRPI0517341A BRPI0517341A BRPI0517341-8A BRPI0517341A BRPI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- compound
- stable
- preparation
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 title abstract 2
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 5
- 150000001875 compounds Chemical class 0.000 title 5
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
- -1 GLP-1 COMPOUND Chemical class 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIçãO FARMACêUTICA ESTáVEL EM PRATELEIRA, MéTODOS PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, PARA O TRATAMENTO DE HIPERGLICEMIA, PARA O TRATAMENTO DE OBESIDADE, DEFICIêNCIA DE CéLULA BETA, IGT OU DISLIPIDEMIA, PARA A PREPARAçáO DE UMA SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1, PARA A PREPARAçãO DE UM COMPOSTO GLP-1 ESTAVEL E PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA ESTáVEL EM PRATELEIRA DE UM COMPOSTO GLP-1, SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1, E, USO DE UMA SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1. Composição farmacêutica estável compreendendo peptídeo insulmotrópico.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401753 | 2004-11-12 | ||
DKPA200401906 | 2004-12-08 | ||
EP05104050 | 2005-05-13 | ||
EP05104172 | 2005-05-18 | ||
PCT/EP2005/055916 WO2006051103A2 (en) | 2004-11-12 | 2005-11-11 | Stable formulations of peptides |
PCT/EP2005/055946 WO2006051110A2 (en) | 2004-11-12 | 2005-11-14 | Stable formulations of insulinoptropic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517341A true BRPI0517341A (pt) | 2008-10-07 |
Family
ID=39560969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517341-8A BRPI0517341A (pt) | 2004-11-12 | 2005-11-14 | composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8748376B2 (pt) |
EP (2) | EP2494983B1 (pt) |
JP (1) | JP5175103B2 (pt) |
KR (1) | KR101340354B1 (pt) |
CN (3) | CN106137952B (pt) |
AU (1) | AU2005303777B2 (pt) |
BR (1) | BRPI0517341A (pt) |
CA (1) | CA2586771A1 (pt) |
ES (2) | ES2458991T3 (pt) |
MX (1) | MX2007005521A (pt) |
PL (1) | PL1817048T3 (pt) |
RU (1) | RU2413530C9 (pt) |
WO (1) | WO2006051110A2 (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
PL1817048T3 (pl) | 2004-11-12 | 2014-07-31 | Novo Nordisk As | Stabilne preparaty peptydów insulinotropowych |
WO2006051103A2 (en) * | 2004-11-12 | 2006-05-18 | Novo Nordisk A/S | Stable formulations of peptides |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
JPWO2009116575A1 (ja) | 2008-03-19 | 2011-07-21 | アークレイ株式会社 | 発色剤の安定化剤およびその用途 |
DK2271347T3 (en) | 2008-03-28 | 2016-08-15 | Hale Biopharma Ventures Llc | Administration of benzodiazepine compositions |
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
DE102010011919A1 (de) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
JP5759211B2 (ja) * | 2011-03-11 | 2015-08-05 | 三洋化成工業株式会社 | 凍結乾燥方法 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN103917241A (zh) | 2011-08-29 | 2014-07-09 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
CA2877056A1 (en) | 2012-07-01 | 2014-01-09 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
WO2014016300A1 (en) | 2012-07-23 | 2014-01-30 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN104902919B (zh) | 2012-12-21 | 2018-11-20 | 赛诺菲 | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 |
CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
CN103405753B (zh) * | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | 稳定的促胰岛素分泌肽水针药物组合物 |
BR112016008115B1 (pt) | 2013-10-17 | 2024-03-12 | Boehringer Ingelheim International Gmbh | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
EP3091964A1 (en) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
BR112016013832A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Gipアゴニスト化合物及び方法 |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
RU2018101070A (ru) * | 2015-06-16 | 2019-07-16 | Сан Фарма Эдвэнтс Рисёрч Кампани Лимитэд | Лираглутидсодержащий состав длительного действия для лечения заболеваний обмена веществ |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
WO2019120480A1 (en) | 2017-12-19 | 2019-06-27 | Novo Nordisk A/S | Solubility of glp-1 peptide |
WO2020104833A1 (en) * | 2018-11-19 | 2020-05-28 | 4P-Pharma | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production |
EP3897570A1 (en) * | 2018-12-19 | 2021-10-27 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising glp-1 analogue |
EA202192094A1 (ru) * | 2019-02-06 | 2021-11-29 | Энзин Биосайенсиз Лимитед | Аналог агониста глюкагоноподобного пептида-1 (glp-1), способ его получения и применение |
WO2020208541A1 (en) * | 2019-04-08 | 2020-10-15 | Enzene Biosciences Limited | Composition comprising glp-1 analogue |
WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
CN116829172A (zh) * | 2021-02-25 | 2023-09-29 | 杭州九源基因工程有限公司 | 一种稳定利拉鲁肽药物制剂的处理方法 |
CN116832147B (zh) * | 2023-08-28 | 2023-11-07 | 谛邈生物科技(北京)有限公司 | Glp1多肽药物冻干闪释片及其制备方法 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468346A (en) | 1983-10-27 | 1984-08-28 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to porcine immunoglobulins |
DE3641115A1 (de) * | 1986-12-02 | 1988-06-16 | Lentia Gmbh | Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins |
AU616411B2 (en) | 1987-05-14 | 1991-10-31 | Commonwealth Scientific And Industrial Research Organisation | Whey protein fractions |
CA1337024C (en) | 1988-06-21 | 1995-09-19 | Yoshie Kurihara | Method for stabilizing taste-modifier |
EP0422124A4 (en) | 1988-06-27 | 1991-10-16 | Genex Corporation | Thermal release of recombinant protein into culture media |
EP0431679B1 (en) | 1989-12-05 | 1994-10-19 | Merck & Co. Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from yeast |
DE4002066A1 (de) | 1990-01-25 | 1991-08-01 | Basf Ag | Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
SE9101381D0 (sv) | 1991-05-07 | 1991-05-07 | Tomas Moks | Peptide hormone solution |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
DE69307505T2 (de) | 1992-05-13 | 1997-07-24 | Sandoz Ag | Opthalmische zusammensetzungen enthaltend ein cyclosporin |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
AU7531094A (en) | 1993-08-24 | 1995-03-21 | Novo Nordisk A/S | Protracted glp-1 |
GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
PT729362E (pt) | 1993-11-19 | 2000-06-30 | Searle & Co | Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
WO1995022560A1 (en) | 1994-02-22 | 1995-08-24 | The Syntex-Synergen Neuroscience Joint Venture | Pharmaceutical formulations of cntf |
US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
ES2211889T3 (es) | 1994-08-31 | 2004-07-16 | Mitsubishi Pharma Corporation | Procedimiento para la purificacion de albumina de suero recombinante. |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
JPH10511365A (ja) | 1994-12-23 | 1998-11-04 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1組成物 |
WO1996024369A1 (en) | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
DK0828753T3 (da) | 1995-06-02 | 2003-06-30 | Novozymes As | A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering |
US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
DE19530865A1 (de) * | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
JPH10101696A (ja) | 1996-08-08 | 1998-04-21 | Shinotesuto:Kk | 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質 |
US6384016B1 (en) | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
CA2278199A1 (en) | 1997-01-20 | 1998-07-23 | Japan Energy Corporation | Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method |
CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
DE69738333T2 (de) | 1997-10-01 | 2008-11-27 | Novadel Pharma Inc. | Nichtpolares Spray zur bukkalen Verabreichung |
RU2218344C2 (ru) | 1997-10-10 | 2003-12-10 | Родиа Лимитед | Усилители адгезии резины |
EP1025126B1 (en) | 1997-10-24 | 2003-04-16 | Genentech, Inc. | Purification of molecules |
CA2312190A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
JP2002504518A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に構造化されたミセルー様凝集体を形成する、25%を超えるヘリックス−含有率を有するglp−1誘導体 |
ATE466028T1 (de) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | N-terminal veränderte glp-1 abkömmlinge |
ATE466027T1 (de) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
US6245572B1 (en) | 1998-05-01 | 2001-06-12 | University Of Tennessee Research Corporation | Flow cytometric characterization of amyloid fibrils |
ES2216447T3 (es) * | 1998-08-17 | 2004-10-16 | Pfizer Products Inc. | Composiciones proteicas estabilizadas. |
US6440930B1 (en) | 1998-09-17 | 2002-08-27 | Eli Lilly And Company | Protein formulations |
ES2249933T3 (es) * | 1998-12-22 | 2006-04-01 | Eli Lilly And Company | Formulacion autoestable de peptido 1 tipo glucagon. |
US6902744B1 (en) | 1999-01-14 | 2005-06-07 | Amylin Pharmaceuticals, Inc. | Exendin agonist formulations and methods of administration thereof |
US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
WO2000055119A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
CA2369839A1 (en) * | 1999-06-25 | 2001-01-04 | Minimed, Inc. | Compositions of insulin and insulin-related peptide for treating diabetes |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
EP1242121B1 (en) | 1999-12-16 | 2005-02-09 | Eli Lilly And Company | Polypeptide compositions with improved stability |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
WO2001051071A2 (en) | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
AU2001220765A1 (en) | 2000-01-24 | 2001-07-31 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
EP1396499A3 (en) | 2000-01-27 | 2004-12-29 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds |
EP1257577B1 (en) | 2000-01-27 | 2004-04-21 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (glp-1) compounds |
US6844321B2 (en) | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
AU2001248277A1 (en) * | 2000-04-06 | 2001-10-23 | Novo-Nordisk A/S | Shock heat treatment of polypeptides |
DZ3388A1 (fr) | 2000-06-16 | 2001-12-27 | Lilly Co Eli | Analogues de peptide 1 du type glucagon |
JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
US7199217B2 (en) * | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
MXPA03005135A (es) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon. |
US20020151467A1 (en) | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
GB2371227A (en) | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
JP4280070B2 (ja) | 2001-02-16 | 2009-06-17 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2) |
AU2002235731A1 (en) | 2001-03-07 | 2002-09-19 | Novo Nordisk A/S | Combined use of derivatives of glp-1 analogs and ppar ligands |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
EP1391209A4 (en) | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
ES2298378T3 (es) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
CN1335182A (zh) | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
US7238663B2 (en) | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
MXPA04003569A (es) | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
EP1344533B1 (en) | 2002-03-15 | 2006-08-23 | Natimmune A/S | Pharmaceutical compositions comprising mannose binding lectin |
JP2005535569A (ja) | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー/エス | Glp−1アゴニスト及び心臓血管合併症 |
ES2308029T3 (es) | 2002-09-25 | 2008-12-01 | Novo Nordisk A/S | Proceso de purificacion que comprende una microfiltracion a temperaturas elevadas. |
US7229554B2 (en) * | 2002-09-25 | 2007-06-12 | Novo Nordisk A/S | Purification process comprising microfiltration at elevated temperatures |
GB0229287D0 (en) | 2002-12-16 | 2003-01-22 | Dna Res Innovations Ltd | Polyfunctional reagents |
WO2004089985A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
MXPA05013048A (es) | 2003-06-03 | 2006-03-02 | Novo Nordisk As | Composiciones peptodicas farmaceuticas estabilizadas. |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
EP1684793B1 (en) * | 2003-11-13 | 2011-09-21 | Novo Nordisk A/S | Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant |
WO2006025882A2 (en) * | 2004-08-25 | 2006-03-09 | The Uab Research Foundation | Absorption enhancers for drug administration |
PL1817048T3 (pl) | 2004-11-12 | 2014-07-31 | Novo Nordisk As | Stabilne preparaty peptydów insulinotropowych |
-
2005
- 2005-11-14 PL PL05817542T patent/PL1817048T3/pl unknown
- 2005-11-14 RU RU2007116157A patent/RU2413530C9/ru active
- 2005-11-14 BR BRPI0517341-8A patent/BRPI0517341A/pt not_active Application Discontinuation
- 2005-11-14 ES ES05817542.3T patent/ES2458991T3/es active Active
- 2005-11-14 MX MX2007005521A patent/MX2007005521A/es active IP Right Grant
- 2005-11-14 CN CN201510572124.1A patent/CN106137952B/zh active Active
- 2005-11-14 EP EP12153063.8A patent/EP2494983B1/en not_active Revoked
- 2005-11-14 CN CN2012102086794A patent/CN102772787A/zh active Pending
- 2005-11-14 WO PCT/EP2005/055946 patent/WO2006051110A2/en active Application Filing
- 2005-11-14 AU AU2005303777A patent/AU2005303777B2/en active Active
- 2005-11-14 ES ES12153063T patent/ES2735533T3/es active Active
- 2005-11-14 KR KR1020077010791A patent/KR101340354B1/ko active IP Right Grant
- 2005-11-14 CA CA002586771A patent/CA2586771A1/en not_active Abandoned
- 2005-11-14 JP JP2007540654A patent/JP5175103B2/ja active Active
- 2005-11-14 EP EP05817542.3A patent/EP1817048B1/en active Active
- 2005-11-14 CN CN201610190775.9A patent/CN105832658B/zh active Active
-
2009
- 2009-12-21 US US12/643,330 patent/US8748376B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1817048B1 (en) | 2014-02-12 |
WO2006051110A2 (en) | 2006-05-18 |
AU2005303777A1 (en) | 2006-05-18 |
CN106137952A (zh) | 2016-11-23 |
CN102772787A (zh) | 2012-11-14 |
RU2413530C9 (ru) | 2021-05-18 |
CN106137952B (zh) | 2020-11-17 |
MX2007005521A (es) | 2007-05-18 |
US8748376B2 (en) | 2014-06-10 |
EP2494983B1 (en) | 2019-04-24 |
RU2007116157A (ru) | 2008-12-20 |
EP2494983A1 (en) | 2012-09-05 |
ES2458991T3 (es) | 2014-05-07 |
EP1817048A2 (en) | 2007-08-15 |
WO2006051110A3 (en) | 2006-11-02 |
CN105832658A (zh) | 2016-08-10 |
ES2735533T3 (es) | 2019-12-19 |
RU2413530C2 (ru) | 2011-03-10 |
KR101340354B1 (ko) | 2013-12-11 |
PL1817048T3 (pl) | 2014-07-31 |
US20100173844A1 (en) | 2010-07-08 |
JP5175103B2 (ja) | 2013-04-03 |
JP2008519809A (ja) | 2008-06-12 |
KR20070084194A (ko) | 2007-08-24 |
AU2005303777B2 (en) | 2010-12-16 |
CN105832658B (zh) | 2020-07-31 |
CA2586771A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517341A (pt) | composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1 | |
CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
BRPI0511420A (pt) | fosforodiamidatos de sulfoniletila | |
DK1636236T3 (da) | Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer | |
BR112012006252A2 (pt) | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". | |
ECSP099662A (es) | Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
DK1791532T3 (da) | Sammensætning i mikropelletform med styret afgivelse af fysiologisk aktive stoffer, fremgangsmåde til deres fremstilling og anvendelse i den zootekniske sektor | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
CL2008002051A1 (es) | Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas. | |
WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
CL2008001103A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros. | |
CL2009001936A1 (es) | Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006). | |
WO2011104381A3 (en) | Stable antibody containing compositions | |
TW200806289A (en) | Sustained-release formulation of zonisamide | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
CR8778A (es) | Revestimientos de azucar y metodos para estos | |
BRPI0908887A2 (pt) | composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
IL175568A (en) | Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B15W | Others matters related to applications: legal action concerning application |
Free format text: "INPI NO 52402.010213/2021-53 ORIGEM: 22A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1070255-48.2021.4.01.3400 NULIDADE DE ATO ADMINISTRATIVO AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL " |